Roxadustat - FibroGen
Alternative Names: ASP 1517; AZD 9941; EVRENZO; Evrenzo; FG-4592Latest Information Update: 10 May 2024
At a glance
- Originator FibroGen
- Developer Astellas Pharma; AstraZeneca; FibroGen
- Class Amides; Antianaemics; Carboxylic acids; Isoquinolines; Small molecules
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
- Preregistration Chemotherapy-induced anaemia
- Discontinued Sickle cell anaemia
Most Recent Events
- 06 May 2024 FibroGen expects NMPA decision for Chemotherapy induced anaemia in the second half of 2024
- 26 Feb 2024 FibroGen and AstraZeneca terminates the license agreement for Roxadustat from AstraZeneca in the United States and other AstraZeneca territories, excluding China and South Korea
- 09 Dec 2023 Efficacy and adverse events data from a phase III MATTERHORN trial in Anaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)